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Stress responses: the contribution of prostaglandin E2 and its receptors 
Tomoyuki Furuyashiki and Shuh Narumiya 
 
Abstract 
Stress is a state of physiological or psychological strain caused by adverse stimuli; responses 
include activation of the sympathetic nervous system, glucocorticoid secretion, and emotional 
behaviors. Prostaglandin E2 (PGE2), through its four receptor subtypes (EP1, EP2, EP3, and 
EP4), is involved in these stress responses. Studies of EP-selective drugs and mice lacking 
specific EPs have identified the neuronal pathways regulated by PGE2. In animals with febrile 
illnesses, PGE2 acts on neurons expressing EP3 in the preoptic hypothalamus. In 
illness-induced activation of the hypothalamic–pituitary–adrenal axis, EP1 and EP3 regulate 
distinct neuronal pathways that converge at the paraventricular hypothalamus. During 
psychological stress, EP1 suppresses impulsive behaviors via the midbrain dopaminergic 
systems. PGE2 induces illness-induced memory impairment, yet also supports 
hippocampus-dependent memory formation and synaptic plasticity via EP2 in physiological 
conditions. In response to illness, PGE2 is synthesized by enzymes induced in various cell 
types inside and outside the brain, whereas constitutively expressed enzymes in neurons 
and/or microglia synthesize PGE2 in response to psychological stress. Dependent on the type 
of stress stimuli, PGE2 released from different cell types activates distinct EP receptors, which 
mobilize multiple neuronal pathways, resulting in stress responses. 
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Key points 
 Prostaglandin (PG) E2 regulates multiple responses to illness and psychological stress via 
distinct PGE2 receptor subtypes  
 During illness-induced fever, PGE2 activates EP3 in neurons in the preoptic 
hypothalamus, which promotes two independent effector mechanisms: increased 
metabolism in brown adipose tissue and vasoconstriction of the skin 
 In illness-induced activation of the hypothalamic–pituitary–adrenal axis, EP1 and EP3 
mediate distinct neuronal pathways that converge on neurons in the paraventricular 
hypothalamus that contain corticotropin-releasing factor 
 Under psychological stress, PGE2–EP1 signaling regulates impulsive behaviors via the 
midbrain dopaminergic system 
 PGE2 regulates illness-induced impairment of memory formation, but under 
physiological conditions (without illness), it supports hippocampus-dependent memory 
formation and synaptic plasticity via EP2 
 PGE2 is synthesized by enzymes induced inside and outside the brain in response to 
illness and by constitutive enzymes in neurons and/or microglia in response to 
psychological stress 
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Introduction 
Stress is a state of physical and psychological stain caused by adverse stimuli (physical, 
mental, or emotional), and evokes common biological responses including fever, 
glucocorticoid secretion, activation of the sympathetic nervous system and emotional 
behaviors (Box 1).
1
 While these stress responses can promote our well-being and survival, 
excessive or abnormal responses to stress can precipitate the development of psychiatric 
disorders, such as depression.
1
 One of the physical stimuli that induces stress is a systemic 
inflammatory challenge, which induces illness-related stress responses (also called sickness 
behaviors or sickness syndrome) including fever, lethargy, hypersomnia, anorexia, and 
hyperalgesia.
2,3
 Administration of NSAIDs (Box 2), which inhibit prostanoid synthesis, can 
treat some of these illness-related stress responses. The involvement of prostanoids in stress 
responses induced by illness have been studied extensively.
4–7
  
The best-studied prostanoid, prostaglandin E2 (PGE2), is produced abundantly in the brain 
in response to illness and mimics stress responses when injected. PGE2 is a bioactive lipid 
derived from arachidonic acid that binds to four cognate G-protein-coupled receptor subtypes 
(EP1, EP2, EP3, and EP4) and is involved in various aspects of inflammation and immunity 
(Figure 1, Box 2).
8
 As each receptor subtype has a specific tissue distribution and induces a 
specific intracellular signaling cascade, the receptors each have distinct functions (some 
functional redundancy might exist between EP2 and EP4, as both are involved in the 
activation of adenylate cyclase). All the EP receptor subtypes have been identified and cloned, 
and mice lacking each EP subtype and drugs selective to each subtype are now available 
(Figure 1, Box 2).
8
 These tools have been used to confirm the involvement of PGE2 in stress 
responses, and to reveal the identity and action of the EP subtype in various illness-related 
behaviors.
8
 Such studies have uncovered unforeseen functions for PGE2 under conditions of 
psychological stress.
9
 In this Review, we will examine these findings, and describe how PGE2 
orchestrates a range of stress responses via the EPs. 
 
Stress responses to illness 
In animal models, administration of lipopolysaccharide (a component of Gram-negative 
bacterial cell walls that act as an endotoxin) and proinflammatory cytokines, such as IL-1, 
can reproduce various illness-related stress behaviors, such as fever, activation of the HPA 
axis, anorexia, lethargy and hypersomnia.
2-7
 Suppression of some of these responses by 
NSAIDs and the effects of injecting various prostaglandins and their analogs into the brain 
suggest that PGE2 is involved in illness-related stress responses in the brain, especially in the 
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hypothalamus.
10,11,34,35
 Studies in EP-knockout mice and with EP-selective drugs have 




PGE2 synthesis during illness 
The brain 
Since PGE2 is synthesized in the brain (especially in the hypothalamus) and is a crucial 
mediator of responses to illness, the site and mode of its synthesis are of intense interest. 
During the first stage of PGE2 synthesis, arachidonic acid is released from membrane 
phospholipids by phospholipase A2 activity. The role of phospholipase A2 in illness-induced 
fever has rarely been analyzed, except with regard to the upregulation of several 
phospholipase A2 isoforms inside and outside the brain following administration of 
lipopolysaccharide.
57
 The phospholipase A2 isoform(s) involved in illness-induced fever 
remain to be clarified.  
PGE2 is produced from arachidonic acid by sequential actions of cyclo-oxygenase (COX) 
enzymes and prostaglandin E synthases (Figure 1a). The involvement of COX2 and 
microsomal prostaglandin E synthase 1 (mPGES1) in responses to illness
29,58–63
 and the 
upregulation of expression of these enzymes by illness-related stimuli are well 
established.
57,64–69
 For example, many studies have shown that lipopolysaccharide and/or 
interleukin (IL)-1 induce the expression of COX2 and mPGES1 in the brain vasculature.64–69 
However, whether endothelial cells of the brain vasculature or perivascular macrophages, or 
both, express these enzymes in response to illness is an area of controversy.
64–69
 Whereas one 
group of studies reported that COX2 and mPGES1 are expressed exclusively in endothelial 
cells,
64,66




The findings that lipopolysaccharide and/or IL-1 induce expression of COX2 and 
mPGES1 in the brain vasculature led to the proposal that blood-borne cytokines could 
stimulate the release of PGE2 from brain vasculature, which in turn acts upon EPs in the brain 
parenchyma (Figure 2a). Since the IL-1 type 1 receptor is predominantly expressed in brain 
endothelial cells,
71,72
 this proposal was tested in an animal model, in which knockdown of the 
IL-1 type 1 receptor in endothelial cells was achieved by inducible expression of an antisense 
RNA molecule.
70
 In this model, induction of COX2 expression was completely abolished and 
almost no febrile response occurred following intravenous injection of IL-170 Furthermore, 
a partial decrease was observed in the febrile response following intraperitoneal injection of 
IL-1.70 This study thus supports the importance of COX2 induction in brain endothelial cells 
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in the stress response to illness-related stimuli.  
The receptor activator of nuclear factor B (RANK) and its ligand, RANKL, have an 
intermediary role in febrile response to illness stimuli—represented by intraperitoneal 
administration of lipopolysaccharide, IL-1 and TNF.73 Gene-deletion studies in astrocytes 
showed that RANK is required for both the febrile response and for IL-1-induced PGE2 
production.
73
 Injection of RANKL into the central nervous system also induces production of 
COX2 in astrocytes.
73
 Thus, current studies in animal models have revealed the brain 
vasculature and astrocytes to be potential sites of PGE2 production during illness (Figure 2a). 
However, COX2 induction in astrocytes as a response to illness-related stress should be 
demonstrated in vivo, and selective deletion of COX2 in cell types suspected to be involved in 
this response should be carried out to verify the role of these cells in responses to 
illness-related stress. 
The contribution of COX1 has been reassessed with regard to early responses to illness, 
especially activation of the hypothalamic–pituitary–adrenal (HPA) axis.62,74,75 Studies in mice 
deficient in either COX1 or COX2 showed that COX1 is involved in early (1 h) responses 
whereas COX2 is involved in late (6 h) responses, specifically the rise in plasma 
corticosterone concentrations following treatment with lipopolysaccharide.
62,75
 This action of 
COX1 seems to be located in the brain, as injection of the COX1 inhibitor SC-560 into the 
central nervous system suppressed the early release of adrenocorticotropic hormone 
(ACTH).
74
 COX1 is constitutively expressed in microglia in the brain,
76
 and its expression is 
induced in endothelial cells and microglia during illness-related stress.
74
 In contrast to 
activation of the HPA axis, studies of COX1-deficient mice indicated that COX1 is not 
involved in any phase of illness-induced fever.
58,59,77
 These findings suggest that in the early 
phases of illness-related stress, febrile and neuroendocrine responses occur via distinct 
mechanisms. In contrast, in the late phase of illness-induced responses, COX2, but not COX1, 
is involved in both fever and activation of the HPA axis.
58,59,62,74,75,77
 As described above, 
COX2 is induced in various cell types inside and outside the brain during illness. Whether 




Studies using peripheral injection of an anti-PGE2 antibody have suggested a crucial role for 
circulating PGE2 during the initial febrile response (Figure 2a).
78
 Thus, neutralizing 
circulating PGE2 with an anti-PGE2 antibody delayed and attenuated 
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lipopolysaccharide-induced fever.
78
 Systemic lipopolysaccharide injection causes an 
immediate increase in blood levels of PGE2,
78
 and intravascular injection of PGE2 can rapidly 
induce fever.
79
 COX2 can be upregulated within 1 h of a stress stimulus in macrophages from 
the lung and the liver, but not those from the brain; therefore, pulmonary and hepatic 
macrophages might be the peripheral origin of PGE2 for the initial febrile response.
78
 
However, the mechanism by which circulating PGE2 elicits fever remains unknown. The 
febrile pathway in the brain is probably involved, as inactivation of the raphe region 
prevented fever from being induced by intravascular injection of PGE2.
80
 The vagus nerve is 
involved in mediation of the febrile response caused by small doses of lipopolysaccharide
81
 or 
IL-1;82 however, vagotomy did not affect the fever induced by intravenous injection of 
PGE2.
80
 Exogenously applied PGE2 can enter the brain during illness-related stress,
83
 but 
whether PGE2 synthesized peripherally can act directly on the central febrile pathway via the 
systemic circulation remains to be examined. 
 
Action of PGE2 during illness 
Fever 
Fever can be generated by various autonomic (e.g. increase in brown adipose tissue 
metabolism, skin vasoconstriction, shivering) and behavioral (e.g. thermal preference, 
postural change) thermoeffector responses.
19
 PGE2 regulates at least two of the autonomic 
mechanisms, namely brown adipose tissue metabolism and skin vasoconstriction. These 
mechanisms are activated by sympathetic premotor neurons in the intermediolateral cell 
column of the spinal cord.
20
 
Microinjection of PGE2 and NSAIDs into various regions of the brain and monitoring local 
concentrations of endogenous PGE2 in the brain revealed that PGE2 is synthesized in the 
preoptic area (POA) and induces the febrile response.
10–12
 However, this central PGE2 action 
was not directly corroborated and its mechanism remained unknown for many years. In 
mouse models of EP deficiency, only EP3-deficient mice did not show a febrile response to 
illness stimuli—systemic injection of lipopolysaccharide and/or IL-1 or injection of PGE2 
into the central nervous system.
13
 When data on the febrile responses of these EP-knockout 
mice were re-examined, the primary role of EP3 in lipopolysaccharide-induced febrile 
response across various doses of lipopolysaccharide was confirmed.
14
 The results of 
pharmacological experiments suggest that EP1 is also involved in illness-induced febrile 
responses.
15
 EP1-deficient mice show an impairment in the febrile response only following 
intraperitoneal injection of a limited dose of lipopolysaccharide, and this impairment in the 
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febrile response was much milder than that of EP3-deficient mice under the same 
conditions.
14
 As EP1-deficient mice show a normal febrile response to injection of PGE2 into 
the central nervous system,
13
 this EP1 action might be exerted outside the brain. 
Consistent with the febrile response to injection of PGE2 into the POA, EP3 is expressed in 
neurons in this brain region.
16,17
 Selective deletion of EP3 in POA neurons in 
conditional-knockout mice showed that expression of EP3 in POA neurons is required for 
lipopolysaccharide-induced fever.
18
 Identification of EP3 in POA neurons has facilitated 
identification of the downstream neural pathway involved in fever generation.
21,23-26
 
The raphe pallidus nucleus (RPa) could have a crucial role in illness-induced febrile 
responses, as pharmacological inhibition of RPa neurons blocked the fever induced by PGE2 
injected into the POA.
21
 Injection of PGE2 into the POA induced expression of c-fos, a marker 
of neuronal activation, in neurons of the rostral RPa.
21
 Indeed, RPa neurons are connected 
directly to the sympathetic premotor neurons in the intermediolateral cell column of the spinal 
cord.
22
 POA neurons that express EP3 are GAD67-positive, putative inhibitory neurons using 
γ-aminobutyric acid (GABA) as a neurotransmitter, and directly project to RPa neurons.21 On 
the basis of these findings, PGE2 was proposed to generate a febrile response by suppressing 
POA neurons that express EP3 (thus disinhibiting RPa neurons).
21
 Further studies have shown 
that EP3-expressing POA neurons regulate brown adipose tissue metabolism and skin 
vasoconstriction via separate pathways.
21,23–26
 Notably, pharmacological inhibition of neurons 
in the dorsomedial hypothalamus blocked thermogenesis in brown adipose tissue but not skin 
vasoconstriction following injection of PGE2 into the POA.
23,24,26
 Two groups of neurons in 
the POA that both express EP3 directly project to the dorsomedial hypothalamus and the RPa, 
respectively.
25
 Currently, POA neurons that express EP3 are thought to control skin 
vasoconstriction through direct projection to the RPa and to control brown adipose tissue 
metabolism through indirect projection to the RPa via the dorsomedial hypothalamus (Figure 
3a). Whether the role of EP3 in the POA is applicable to other effector mechanisms, such as 
shivering, for illness-induced fever remains unknown. 
 
Hyperthermia 
The POA is not involved in every type of illness-induced fever.
27
 For example, animals given 
lipopolysaccharide can develop hyperthermia by selecting warmer environments owing to a 
rise in the set point of their body temperature. This hyperthermia induced by thermal 
preference does not involve the POA, as it was not eliminated by POA lesions.
27
 Whether EP3 
is involved in this type of hyperthermia remains unknown. 
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Psychological stress can also induce hyperthermia, but EP3 does not seem to be involved 
in this response.
13,14
 Thus, different mechanisms, at least in part, underlie 
psychological-stress-induced hyperthermia and illness-induced fever (Box 3). 
 
Hypothermia  
High doses of lipopolysaccharide, such as an intraperitoneal injection of 1 mg/kg, might cause 
hypothermia instead of fever.
28
 Results from pharmacological studies suggest that prostanoids 
are also involved in this hypothermic response.
29,30
 Injection of ONO-AE1-329, a selective 
EP4 agonist, into the central nervous system induced hypothermia, which suggests that EP4 
might regulate this response.
31
 EP4 is expressed in various hypothalamic nuclei implicated in 
thermoregulation.
17,32
 For example, EP4 is expressed in POA neurons as EP3, and 
lipopolysaccharide activates these EP4-expressing neurons.
17
 As stimulation of EP3 and EP4 
elicits opposite signaling actions—typically decreasing and increasing cyclic AMP (cAMP) 
production, respectively
8—the presence of these two receptors in the POA could exert 
opposite actions in thermoregulation. Studies in EP4-deficient mice are warranted, to establish 
the role of EP4 in illness-induced hypothermia. 
 
Activation of the HPA axis 
The HPA axis is the neuroendocrine system by which corticotropin-releasing factor (CRF) 
from neurons in the paraventricular hypothalamus (PVH) induces ACTH release from the 
pituitary gland, which in turn stimulates glucocorticoid production in and secretion from the 
adrenal cortex.
33
 Systemic injection of NSAIDs blocks activation of the HPA axis induced by 
illness-related stimuli, although the effect is often partial.
5
 Thus, illness-induced activation of 
the HPA axis seems to have prostaglandin-dependent and prostaglandin-independent 
components. Results from studies using microinjection of PGE2, its analogs and NSAIDs into 
the brain suggest that PGE2 synthesized in the POA is also critical for activation of the HPA 
axis in response to illness-related stressors.
34,35
 Microinjection of PGE2 into the PVH or the 
median eminence (through which CRF-containing PVH neurons secrete CRF from their axon 
terminals) also activates the HPA axis.
36,37
 
An examination of ACTH release following lipopolysaccharide injection in mice deficient 
in various EPs revealed the mechanism of PGE2 action in the HPA-axis response to illness.
38
 
Consistent with previous findings, indomethacin-sensitive and indomethacin-insensitive 
components of ACTH release were identified in studies of intraperitoneal lipopolysaccharide 
injection.
38
 Mice deficient in either EP1 or EP3 had impaired ACTH release. Both EP1 
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deletion and EP3 deletion suppressed ACTH release to the same extent as administration of 
indomethacin did. This finding suggests that both EP1 and EP3 are required for 
prostaglandin-dependent ACTH release. 
Although the sites of action of EP1 and EP3 remain to be determined, these two receptors 
seem to stimulate the HPA axis via distinct neural pathways that ultimately converge.
38
 
Studies of c-fos mapping suggest that EP1, but not EP3, is involved in the activation of 
neurons in the central nucleus of the amygdala, and that both EP1-mediated and 
EP3-mediated neural pathways are involved in activation of PVH neurons.
38
 Illness-related 
stressors increase levels of PGE2 in the PVH as well as in the POA
12
 and EP1 is localized at 
synaptic structures on PVH neurons.
38
 In hypothalamic slices, PGE2 depolarizes 
CRF-containing PVH neurons,
39
 and injection of PGE2 into the PVH promotes ACTH 
release.
37
 These results indicate that EP1 probably facilitates neurotransmitter release from the 
axon terminals that are formed on CRF-containing neurons in the PVH. However, which 
neurotransmitter(s) EP1 regulates is currently unknown. In addition, since EP1 is expressed in 
the presynaptic terminal on neurons in the central nucleus of the amygdala,
38
 this same 
receptor could also act in the latter brain region to activate PVH and induce release of ACTH. 
Neurons in the central nucleus of the amygdala indirectly project to the PVH via the bed 
nucleus of the stria terminalis.
33
 One report suggested that lesions in the central nucleus of the 
amygdala resulted in considerably reduced IL-1-induced ACTH release.40 These findings 
suggest that EP1 could act in the PVH both directly and indirectly (through the central 
nucleus of the amygdala). 
In addition to the PVH, the POA is involved in the effect of PGE2 on activation of the HPA 
axis.
34,35
 EP3 has a critical role in illness-induced fever; therefore, EP3 might activate the 
HPA axis in a similar manner to its action in fever, because GABAergic neurons in the POA 
are thought to project directly to the PVH.
33
 As PGE2 probably suppresses EP3-expressing 
POA neurons to produce a febrile response,
21
 PVH neurons could also be disinhibited to 
enable the activation of the HPA axis. 
Alternatively, EP3 is expressed in various catecholaminergic neuron groups,
41
 and one 
such site, the rostral ventrolateral medulla, has been proposed to mediate illness-induced 
activation of the HPA axis.
42
 EP3 might, therefore, have a role in activating neurons in this 
site. Collectively, these findings suggest that EP1 and EP3 activate distinct pathways in 
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Anorexia  
In addition to febrile and neuroendocrine responses, illness-related stress also induces other 
behavioral changes, such as anorexia.
2,3,7
 Studies using COX inhibitors and knockout mice 
suggest that prostanoids are involved in illness-induced anorexia.
43–45
 As administration of 
COX inhibitors or COX2 deletion only partially reverses illness-induced anorexia,
43-45
 both 
prostaglandin-dependent and prostaglandin-independent mechanisms for the development of 
anorexia seem to exist. 
Two research groups have reported that mice lacking mPGES1 did not develop anorexia 
when they were injected intraperitoneally with IL-1unlike their wild-type counterparts.46,47 
These findings clearly show that PGE2 signaling has a role in illness-induced anorexia. 
However, mPGES1 is not involved in anorexia induced by administration of 
lipopolysaccharide.
46
 By contrast, NSAIDs reduced the severity of anorexia induced by 
various illness-related stressors, including IL-1 and lipopolysaccharide.43–45 Thus, 
mPGES1-independent prostanoid synthesis could mediate lipopolysaccharide-induced 
anorexia. 
One report indicates that EP4 can induce anorexia.
48
 Administration of ONO-AE1-329, a 
selective EP4 agonist, to the central nervous system induced anorexia, mimicking the action 
of PGE2.
48
 The anorexic effects of PGE2 and ONO-AE1-329 were blocked by ONO-AE3-208, 
a selective EP4 antagonist, but not by selective antagonists of the other EPs. Although no 
studies have examined illness-induced anorexia in EP4-deficient mice, one report using 
EP1-knockout and EP3-knockout mice showed that neither of these receptor subtypes is 
involved in tumor-induced anorexia.
49
  
A primary neuronal circuit that controls feeding behavior is located in the hypothalamus 
(Figure 3c).
50
 The arcuate nucleus of the hypothalamus senses peripheral hormonal signals, 
such as insulin and leptin, and its neurons project to other hypothalamic areas (mainly the 
dorsomedial hypothalamus, the ventromedial hypothalamus, PVH, and the lateral 
hypothalamic area) involved in the metabolic regulation of feeding.
50
 The nucleus tractus 
solitarius receives peripheral satiety signals via vagal afferent fibers and has reciprocal 
connections with the PVH.
 50
 EP4 is expressed in both the PVH and the nucleus tractus 
solitarius.
32
 EP4 is also expressed in the bed nucleus of the stria terminalis, which together 
with the PVH has been implicated in anorexia induced by CRF, a stress-related molecule.
51
 
EP4 is dramatically upregulated in these areas in response to illness-related stress.
32
 
Another possible connection between EP4 and feeding control is histamine. EP4 is 
expressed in histaminergic neurons in the tuberomammillary nucleus of the hypothalamus, 
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and ONO-AE1-329, a selective EP4 agonist, stimulated histamine release to induce 
wakefulness.
52
 Histamine is also an anorectic substance,
53
 and seems to be involved in 
illness-induced anorexia: central injection of -fluoromethylhistidine, a blocker of histamine 
synthesis, attenuated the anorexia induced by IL-1.54 Thus, EP4 could cause anorexia via 
inducing histamine release. In summary, EP4 seems to be a good candidate for central 





Suppression of social behavior 
Administration of indomethacin abrogates the reduction in social behaviors, such as 
sniffing and grooming, induced by IL-156Prostaglandins could be involved in this 
mechanism.
56
 The identity and neural mechanism of this presumed prostaglandin-mediated 
action remain unknown. 
 
Impaired learning and memory formation  
Illness-related stress impairs memory formation via the effects of cytokines and prostanoids.
7
 
Systemic injection of lipopolysaccharide and IL-1 impairs memory formation in various 
behavioral models.
95,96
 Hippocampus-dependent memory formation is especially 
impaired.
95,96
 COX inhibitors can attenuate illness-induced memory impairment, which 
suggests that prostanoids might be involved in this process.
97–100
 Notably, microinjection of 
naproxen, a COX inhibitor, into the hippocampus reverses the impairment in 
hippocampus-dependent memory following injection of IL-1 into the hippocampus.100 
Furthermore, injection of PGE2 into the hippocampus mimics the memory-impairing effect of 
IL-1 injection.98,100 The results of these studies suggest that PGE2 acts downstream of IL-1 
in the hippocampus, and causes illness-induced memory impairment. The role of prostanoids 
in illness-induced memory impairment has been characterized using a transgenic mouse 
model, in which chronically raised levels of IL-1 could be induced with spatiotemporal 
specificity.
101
 In this model, a chronic increase in levels of IL-1 in the hippocampus impairs 
long-term contextual and spatial memory.
102,103
 This IL-1 overexpression induced the 
expression of COX1 and mPGES1 and enhanced PGE2 production.
103,104
 Many 
COX1-positive cells are microglia.
104
 Importantly, deletion of the gene encoding COX1 
eliminated the memory impairment induced by IL-1 overexpression in the hippocampus.104 
Deletion of this gene also reversed IL-1-induced increase in levels of PGE2, but not the 
increases in levels of various cytokines (such as TNF and IL-6) and chemokines (such as 
  
   12 
CC-chemokine ligand 2 and CXC-chemokine ligand 2).
104
 These findings suggest that a 
COX1-derived prostanoid, perhaps PGE2, induces memory impairment independent of other 
cytokines. 
 Which EP subtype is involved in memory impairment has not been fully examined. 
EP2 is a plausible candidate, as systemic injection of lipopolysaccharide increases expression 
of EP2 and EP4 in the brain, and EP2 is expressed in the hippocampus.
32
 As described in 
detail below, EP2 is involved in various forms of long-term synaptic plasticity in the 
hippocampus.
105–108
 EP3 is another candidate, as injection of IL-1 into the central nervous 
system raised expression of EP3 in the hippocampus,
109
 and EP3 mediates suppression of 




Responses to psychological stress 
Impulsive behavior 
A study in EP1-deficient mice discovered that PGE2 signaling is crucial for regulating 
impulsive behaviors related to acute psychological stress.
 84
 Thus, EP1-deficient mice showed 
impulsive aggression and deficits in social behavior in response to psychological stress. 
EP1-deficient mice also showed impaired cliff avoidance and an exaggerated startle response 
to acoustic stimuli.
84
 Some of these behaviors can be mimicked by administration of 
ONO-8713, a selective antagonist of EP1, to wild-type mice.
 84
 Collectively, EP1 deficiency 
or antagonism seem to induce ‘emotional impulsivity’ after Soubrié’s definition, a tendency of 
disinhibiting otherwise restrained bhavior.
REFa
 The central injection of ONO-DI-004, a 
selective EP1 agonist, suppressed aggressive behavior, which suggests that this EP1 action 
occurs in the brain.
84
 Further studies have demonstrated that EP1 acts, at least in part, on the 
dopaminergic system to exert such actions (Figure 4, Box 4).
84,85
 Impulsive behaviors of 
EP1-deficient mice were suppressed when they were given dopamine receptor antagonists.
84
 
In addition, results from biochemical and microdialysis experiments showed that the basal 
level of dopamine release is increased in EP1-deficient mice compared with wild-type 
mice.
84,85
 Results from slice electrophysiology studies suggest stimulation of EP1 by 
ONO-DI-004, an EP1 agonist, augments GABAergic inputs to dopaminergic neurons in the 
substantia nigra pars compacta.
85
 EP1 is consistently localized at the GABAergic terminals on 
these neurons, which are at least in part derived from neuronal projections in the striatum.
85,86
 
These results suggest that PGE2–EP1 signaling augments the negative feedback to midbrain 
dopamine neurons in a direct pathway from the striatum. 
 Dopaminergic disinhibition associated with EP1 deficiency should cause behavioral 
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impulsivity through some dopaminoceptive area(s). Although this issue remains to be 
examined, several dopaminoceptive areas, such as the prefrontal cortex and the amygdala, are 
critical for impulsivity.
88
 Alternatively, dopamine in the nucleus accumbens suppresses and 
enhances excitatory inputs from the prefrontal cortex and the hippocampus, respectively.
89
 
Enhanced dopamine release in EP1-deficient mice could disengage the nucleus accumbens 
from the top-down signal from the prefrontal cortex, a pathway that negatively regulates 
impulsivity in animals.
90
 These possibilities remain to be explored. 
Since the above EP1-mediated response takes place immediately upon psychological stress, 
the release of PGE2 for this EP1 action should involve the constitutive COX–prostaglandin E 
synthase pathway. COX1 and COX2 are constitutively expressed in microglia and neurons, 
respectively.
76
 Various psychological stressors, such as forced swim and restraint, increase 
COX2 expression in cortical pyramidal neurons.
91,REFb
 At the same time, psychological stress 
alters gene expression profiles and morphology of microglia.
92,93
 Thus, both neurons and 




Interestingly, despite the presence of a hyperdopaminergic state, EP1 deficiency did not cause 
hyperlocomotion,
84
 a phenotype of raised dopamine levels in the striatum.
87
 This discrepancy 
could be explained by impairment of another EP1 action that facilitates dopamine receptor 
signaling in the striatum.
86
 EP1 is expressed in the cell bodies of spiny striatal projection 
neurons, and augments both dopamine D1 and D2 receptor signaling in an agonist-dependent 
manner. Dependent on where and when PGE2 is produced, therefore, PGE2–EP1 signaling can 
regulate the outcome of the dopaminergic activity in either direction. The lack of 
hyperlocomotion in EP1-deficient mice suggests that these two EP1 actions are normally 
balanced in the striatum. 
 
Alterations in learning and memory (level 2 subheading) 
Illness-related stress and psychological stress alter the ability of animals to learn in a 
complicated manner. Acute and chronic psychological stress either facilitates or suppresses 
memory formation, effects often linked to the actions of glucocorticoids.
1,94
 However, results 
from several studies have indicated that cytokines and prostanoids are also involved in 
learning and memory under conditions of psychological stress.
107,108,110-115,117
 
 Many behavioral tasks used to evaluate learning and memory employ stimuli that are 
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psychologically aversive for rodents, such as water immersion in the Morris maze and foot 
shock in fear conditioning. These tasks can potentially be used to evaluate memory formation 
under psychological stress, although the exact effects of psychological stress should be 
identified by comparing the findings obtained using these behavioral tasks to those obtained 
in situations without aversive stimuli, such as reward-oriented spatial learning. Using the 
Morris water maze and context-dependent fear conditioning, involvement of IL-1 and PGE2 
in memory formation per se in these tasks has been revealed.
110–115
 For example, mice that 
lack the IL-1 receptor show deficits in contextual fear conditioning and in the spatial 
memory.
111
 Results from previous studies also suggest that prostaglandins are involved in 
hippocampus-dependent spatial memory.
108,112-115
 Thus, COX inhibitors impaired the 
acquisition and retention of spatial memory in the Morris water maze task.
112,113
 Similarly, 
injection of celecoxib, a selective inhibitor of COX2, into the hippocampus blocked spatial 
memory in the Morris water maze task,
114,115
 indicating that prostaglandins might be involved 
in the hippocampus.  
 Consistent with these effects of COX inhibitors and the actions of EP2 in synaptic 
plasticity described below, EP2-deficient mice show various memory disturbances.
107,108
 For 
example, EP2-deficient mice had impaired spatial memory during the Morris water maze 
task.
108
 EP2-deficient mice also showed a deficit in prepulse inhibition (suppression of 
sensory-evoked motor response due to a prior weak sensory stimulus) and heightened 
anxiety.
107
 This latter EP2 action might be attributable to areas of the brain other than the 
hippocampus, as EP2 is also expressed in other areas, including the amygdala.
32
 Another 
study examined the role of IL-1 in a particular type of psychological stress on 
hippocampus-dependent memory. 
117
 Social isolation, a type of psychological stress, impairs 
context-dependent fear conditioning.
116
 Injection of an IL-1 receptor antagonist into the 
central nervous system eliminated this effect of social isolation, which indicates that IL-1 
signaling has a role in the brain.
117
 However, the function of prostanoid signaling in this 
model has not yet been examined. 
 
PGE2 signaling in synaptic plasticity  
Consistent with above behavioral findings under illness-related and psychological stress, 
results from electrophysiological studies have demonstrated that PGE2 is involved in 
excitatory synaptic transmission and long-term plasticity (Figure 5).
105–108,113,118–121
 For 
example, the addition of COX inhibitors to a hippocampus slice blocks the induction of 
long-term potentiation at the perforant path–dentate gyrus (PP–DG) excitatory synapse, 
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deficits that are reversed by exogenous application of PGE2.
113,118,119
 Long-term potentiation 
at this synapse was consistently impaired in EP2-deficient mice.
108
 Thus, PGE2–EP2 signaling 
seems to be crucial in long-term potentiation at the PP–DG synapse in the hippocampus. 
Furthermore, expression-knockdown experiments using RNA interference showed that 
PGE2–EP2 signaling is also necessary in long-term potentiation at the layer IV–layer II–III 
excitatory synapse in the visual cortex.
106
 In contrast to EP2, EP3 knockdown by RNA 
interference augmented long-term potentiation at this synapse in the visual cortex, which 
indicates that EP3 is inhibitory.
106
 
Although EP2 is involved in long-term potentiation at both the PP–DG synapse in the 
hippocampus and the layer IV–layer II–III synapse in the visual cortex, different subcellular 
localizations of EP2 have been shown at these two synapses.
105,106
 Immunostaining suggests 
that EP2 is localized at the presynaptic structure of primary neurons in the hippocampus and 
at postsynaptic structures of neurons in the visual cortex,
105,106
 although EP2 localization in 
vivo has not been examined. Ca
2+
 influx through the N-methyl D-aspartate-type glutamate 
receptor activates PGE2 production by COX2,
122
 and COX2 is located at postsynaptic 
structures in various types of neurons.
105,106
 On the basis of these findings, PGE2 released 
from the postsynaptic site was proposed to act on presynaptic EP2 as a retrograde messenger, 
which mediates signaling from a postsynaptic structure to an adjacent presynaptic structure, in 
the PP–DG synapse,105 and postsynaptically released PGE2 acts on postsynaptic EP2 in the 
layer IV–layer II–III synapse.106 
Long-term potentiation at the Schaffer collateral–CA1 synapse was not impaired in 
hippocampal slices from EP2-deficient mice, which suggests that EP2 is not involved in all 
kinds of long-term potentiation.
107
 Rather, EP2 deficiency impaired long-term depression at 
this synapse.
107
 Prostaglandins also seem to mediate long-term depression at the PP–DG 
synapse, given that NS-398, a COX2 inhibitor, blocked long-term depression as well as 
long-term potentiation at this synapse.
120
 Long-term depression at the parallel fiber–Purkinje 
cell synapse in the cerebellum also seems to depend on prostanoid signaling.
121
 Several COX2 
inhibitors, such as NS-398 and DUP 697, suppressed long-term depression at this synapse, 
and this blockade was reversed by exogenously applied prostaglandin D2 or PGE2.
121
 




The development of EP-knockout mice and EP-selective drugs has enabled the identification 
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of multiple adaptive functions of PGE2 under illness-related stress, each of which is mediated 
by a distinct EP subtype.
8,9,13,14,18,31,38,73
 These molecular tools have also provided evidence 
that PGE2 signaling has unexpected actions under conditions of psychological stress and in 
physiological brain functions, such as the role of EP1 in suppressing impulsive behaviors via 
the dopaminergic system and that of EP2 in hippocampus-dependent learning and synaptic 
plasticity.
84-86,105-108
 Dependent on the type of stressor present, PGE2 is released from various 
cell types, and acts in the vicinity of its synthesis. Upon illness-related stress, blood-borne 
cytokines (such as IL-1) induce the production of COX2 and mPGES1 in several types of 
cells inside and outside the brain, and these enzymes, in turn, synthesize PGE2.
57,64-70,73,78
 
Cooperative actions of PGE2 and cytokines are also key features in the immune system and 
bone metabolism.
8
 By contrast, psychological stimuli are perceived as stress through neuronal 
connections, which in turn affects neuronal pathways involved in behavioral outcomes.
1
 
Although both IL-1 and PGE2 clearly have roles in responses to psychological stress, the 
mechanisms to explain how these two molecules are released and their involvement in the 
neural cascades from stressful stimuli to behavioral responses remain elusive. Results from 
clinical studies have shown the relevance of prostanoids in patients with schizophrenia or 
major depression.
123
 As chronic psychological stress precipitates psychiatric disorders, the 
number of studies on the role of prostanoids in animal models of chronic stress is 
increasing.
124–126
 Whether and how the PGE2-dependent mechanisms involved in responses to 
stress contribute to mental illnesses is also an exciting question. 
 
Review criteria 
A search for original articles published between 1998 and April of 2010 and focusing on 
neural functions of prostaglandin E2 in stress responses was performed in PubMed. The 
search terms used were “prostaglandin” and “brain”, and relevant articles were manually 
selected from the resultant list. We also searched the reference lists of identified articles for 
relevant papers. 
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Figure legends 
Figure 1. PGE2 synthesis, prostaglandin receptor subtypes and subtype-selective compounds. 
a | PGE2 is synthesized by sequential catalysis involving COX1, COX2 and PGESs. NSAIDs, 
including aspirin and indomethacin, suppress prostaglandin production by inhibiting COX. b | 
The four subtypes of prostaglandin E receptors (EP1–EP4) are encoded by different genes. 
These receptors are divided into three groups according to their major signaling pathways: 
EP1 is linked to increases in levels of intracellular Ca
2+
, EP2 and EP4 are linked to increases 
in levels of cAMP via Gs, and EP3 is linked to decreases in levels of cAMP via Gi. c | 
Some EP-subtype-selective agents. Only representative compounds are shown. Abbreviations: 
COX, cyclo-oxygenase; Gi, inhibitory G-protein subunit; Gs, stimulatory G-protein 
subunit; PGES, prostaglandin E synthase. 
 
Figure 2. Proposed sites of PGE2 production during illness and psychological stress. a | 
Various studies have shown that illness-related stressors, such as lipopolysaccharide and 
IL-1, induce expression of COX2 in endothelial cells and/or perivascular macrophages in the 
brain, which in turn induces synthesis of PGE2. RANKL–RANK signaling can also mediate 
IL-1-induced production of PGE2 in the hypothalamus and COX2 induction in astrocytes. 
The major site of PGE2 production in the brain involved in stress responses to illness remains 
to be elucidated. Furthermore, PGE2 from peripheral macrophages in the lungs and liver 
mediates the initial febrile response (within 1 h) to illness. b | COX1 and COX2 are 
constitutively expressed in microglia and cortical pyramidal neurons, respectively. Under 
conditions of psychological stress, one or both of these constitutively expressed COX 
isoforms could conceivably be responsible for PGE2 production. Abbreviations: COX, 
cyclo-oxygenase; IL, interleukin; PGE2, prostaglandin E2. 
 
Figure 3. Neuronal pathways involved in stress responses to illness. a | Pathways for 
autonomic mechanisms involved in the febrile response. EP3 localizations are shown in red. 
The neural pathway for shivering (another critical thermoeffector) is not shown, as the role of 
PGE2 in this response remains unknown. b | Pathways for the hypothalamus–pituitary–adrenal 
response. Putative localizations of EP1 and EP3 receptors in these pathways are shown in 
yellow and red, respectively. c | Pathways involved in anorexia. Putative EP4 localizations are 
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shown in green. In a | and b | excitatory and inhibitory neurons involved in each pathway are 
shown in purple and blue, respectively. The use of these specific colors does not, however, 
exclude the presence of other neuron types in a given area. Abbreviations: ACTH, 
adrenocorticotropic hormone; ARC, arcuate nucleus of the hypothalamus; BNST, bed nucleus 
of the stria terminalis; CeA, central nucleus of the amygdala; CRF, corticotropin-releasing 
factor; DMH, dorsomedial hypothalamus; His, histamine; LHA, lateral hypothalamic area; 
ME, median eminence; POA, preoptic area; NA, noradrenaline; NTS, nucleus tractus 
solitarius; PVH, paraventricular hypothalamus; RPa, raphe pallidus nucleus; RVLM, rostral 
ventrolateral medulla; TMN, tuberomammillary nucleus; VMH, ventromedial hypothalamus. 
 
Figure 4. EP1-mediated regulation of dopaminergic systems under psychological stress. a | 
Dopaminergic neurons in the SNc and the VTA and their projections are shown in green. 
Circuits from striatal neurons that express dopamine receptors D1 and D2 are shown in black. 
EP1 localizations are shown in yellow. b | Psychological stress seems to induce PGE2 
production in the SNc and striatum. In the SNc, PGE2-mediated EP1 activation occurs at the 
GABAergic presynaptic terminals on dopaminergic neurons, and augments GABA release 
that negatively modulates the activity of these neurons. In the striatum, PGE2 activates EP1, 
which is expressed on both D1-expressing neurons and D2-expressing neurons, and facilitates 
signaling of both dopamine receptors. Abbreviations: CPu, caudate putamen; EP, PGE2 
receptor; GABA, γ-aminobutyric acid; GPe, external globus pallidus; GPi, internal globus 
pallidus; NAc, nucleus accumbens; PFC, prefrontal cortex; PGE2, prostaglandin E2; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic 
nucleus; VTA, ventral tegmental area. 
 
Figure 5. Proposed mechanisms in EP2-mediated control of synaptic plasticity. a | In the 
hippocampus, EP2 is suggested to function at the PP–DG synapse for long-term potentiation 
and at the SC–CA1 synapse for long-term depression of responses. b | Proposed mechanisms 
for EP2 actions on long-term potentiation of neuronal circuits. Ca
2+
 influx through NMDA 
receptor (NR) during synaptic inputs evokes PGE2 production from arachidonic acid (AA) via 
COX-2 and PGES activity at the postsynaptic structure. PGE2 released is suggested to act on 
either presynaptic structure (in the hippocampus) or postsynaptic structure (in the visual 
cortex) via EP2. To cause long-term potentiation, cAMP increase downstream of EP2 could 
increase the probability of neurotransmitter release and/or the trafficking of AMPA-type 
glutamate receptor (AMPA-R). Abbreviations: AA, arachidonic acid; AMPA-R, AMPA-type 
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glutamate receptor; CA, cornus ammonis; DG, dentate gyrus; EC, entorhinal cortex; EP, 
prostaglandin E2 receptor; NR, N-methyl-D-aspartate-type glutamate receptor; PGES, 
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Box 1. Stress, stressors and stress responses 
Stress is a concept that was developed to explain the similarity of biological responses to 
various external and internal stimuli, such as illness and psychological stimuli. Stress is a state 
of physical and psychological stain caused by adverse stimuli, which results in adaptive 
responses to restore our bodily status.
1
 Stimuli that cause stress are called stressors, and 
biological responses to these stressors are called stress responses. However, the mechanisms 
underlying stress responses are still being investigated. The extent to which similar or 
overlapping mechanisms regulate stress responses across stressors remains unknown.  
 Illnesses attributable to systemic inflammation are typically associated with a cluster 
of biological responses. The pattern of responses depends on the severity and time course of 
the illness.
2,3,127
 At the onset of illness (or if illness is mild) active defense mechanisms, such 
as fever, wakefulness, hypertension, hyperalgesia, and generalized motor agitation, typically 
occur. By contrast, if illness is severe or prolonged, passive defense mechanisms including 
lethargy, analgesia and hypersomnia become dominant to avoid further energy expenditure. At 
this stage, either hyperthermia or hypothermia might occur owing to an increased 
susceptibility to the ambient temperature. 
 Acute exposure to fearful or anxiogenic stimuli, such as the presence of a predator or 
being in an unprotected place, activates a coping strategy called the ‘flight or fight’ response, 
a preparatory response to facilitate escape and self-defense. This response manifests as 
activation of the sympathetic nervous system (for example, increased heart and lung action, 
hyperthermia and pupil dilation) and increased levels of glucocorticoids. Chronic exposure to 
such stimuli often precipitates exhaustion and depression.
1
 Thus, both illness and 
psychological stimuli result in a dynamic course of adaptive responses, either active or 
passive, depending on bodily demands. 
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Box 2. NSAIDs, prostanoids and their receptors 
The NSAIDs are drugs with analgesic, antipyretic and anti-inflammatory actions that do not 
have a steroid backbone. Various NSAIDs, such as aspirin, indomethacin and ibuprofen, have 
been developed. Their actions are mostly attributable to the blockade of cyclo-oxygenase 
(COX) enzymes, which are responsible for prostanoid synthesis.
128
 
The prostanoids are a family of bioactive lipids produced from C20-unsaturated fatty acids, 
such as arachidonic acid. They are synthesized throughout the body in response to various 
noxious stimuli and tissue injuries, and have multiple physiological and pathological roles in 
inflammation and immunity, cardiovascular homeostasis, bone metabolism and illness-related 
stress responses. The prostanoids include prostaglandin (PG) PGD2, PGE2, PGF2, PGI2 and 
thromboxane A2,
8
 all of which are formed by the sequential actions of two isoforms of COX 
(COX1 and COX2) and three isoforms of PGE synthase (PGES): cytosolic PGES, 
microsomal PGES1 and microsomal PGES2. Expression of COX2 and mPGES1 is induced 
by illness-related stressors such as lipopolysaccharide and proinflammatory cytokines. 
Each prostanoid binds to its cognate G-protein-coupled receptor, for example, PGE2 has 
four receptor subtypes (EP1, EP2, EP3 and EP4).
8
 These receptors are categorized into three 
groups according to their major signaling pathways: those coupled to Ca
2+
 increase (EP1), 
those coupled to cyclic AMP increase (EP2 and EP4), and those coupled to cyclic AMP 
decrease (EP3). These receptors show distinct tissue expression and cell localization, enabling 
them to exert specific functions.
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Box 3. Stress-induced hyperthermia 
Acute psychological stress induces hyperthermia. Some animal studies showed that NSAIDs 
block the hyperthermia response to psychological stressors, such as exposure to an open field 
or a cage of another individual, whereas other studies did not show this effect.
129
 However, as 
NSAIDs also exert some prostaglandin-independent effects, these pharmacological studies are 
not conclusive. Gene-deletion studies do not yet support a role of prostaglandin E2 signaling 
in stress-induced hyperthermia. Mice lacking either microsomal prostaglandin E synthase 1 or 
prostaglandin E2 receptor (EP) 3 did not develop illness-induced fever, whereas these mice 
showed a normal hyperthermia response to psychological stress.
13,14,61
 EP1-deficient mice 
also demonstrated a normal stress-induced hyperthermia response.
14
 By contrast, 
stress-induced hyperthermia is specifically sensitive to anxiolytics
129,130
 and blockade of the 
corticotropin-releasing factor receptor in the brain.
131
 Thus, the mechanisms of stress-induced 
hyperthermia and illness-induced fever seem to differ. 
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Box 4. Midbrain dopaminergic systems 
Midbrain dopaminergic neurons are mainly located in the ventral tegmental area and the 
substantia nigra pars compacta.
132
 Dopaminergic neurons in the ventral tegmental area project 
mostly to the medial prefrontal cortex and the nucleus accumbens. Substantia nigra pars 
compacta dopaminergic neurons primarily project to the dorsal striatum or the caudate 
putamen. The dorsal striatum contains two types of projection neurons: those that express the 
dopamine D1 receptor and the dopamine D2 receptor, respectively. D1-expressing neurons 
project directly to the internal globus pallidus and the substantia nigra pars reticulata, which 
in turn project to the thalamus and the superior colliculus. A subset of D1-expressing neurons 
in the striatum provides negative feedback control of dopaminergic neurons.
132
 D2-expressing 
neurons project to the external globus pallidus, which in turn project to the internal globus 
pallidus and substantia nigra pars reticulata, mostly via the subthalamic nucleus. 
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